By MALIKA AMMAM, PHD A recent study suggests that RNA fragments called microRNAs (miRNAs), long thought of as genetic “junk,” actually control the production of endothelial cells, whose over-proliferation is responsible for the development of pulmonary hypertension (PH). The study, published in the Experimental Biology...
Βy ALISA WOODS, PHD Researchers from Japan described ways to predict the progression and severity of pulmonary hypertension (PAH) in people with left heart disease. Their paper, a review of standard and emerging methods for assessing the lung disease, is titled “The...
BY MARGARIDA AZEVEDO Over the last decade, new oral therapy agents in the form of pills used for the management and treatment of pulmonary arterial hypertension (PAH) have been integrated and improved, such as ERAs, PDE-5 inhibitors, and prostacyclin...
By ANA PAMPLONA, PHD A new study identifies the hemodynamic variables that distinguish patients with idiopathic pulmonary arterial hypertension (PAH) from those with isolated post-capillary pulmonary hypertension (PH), a finding that will help to diagnose and treat more accurately and effectively patients with these...
By ALISA WOODS, PHD Recent advances in pulmonary arterial hypertension therapy may be used for sarcoidosis-associated pulmonary hypertension A recent article suggests prostacyclin therapy, which is used for the treatment of pulmonary arterial hypertension (PAH), may also be useful for treating...
By Bruno Castro, PhD In a recent study entitled, “Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension” published in the prestigious New England Journal of Medicine, a worldwide team of researchers demonstrated that treatment combining ambrisentan and tadalafilsignificantly improves the clinical condition of Pulmonary...
By Malika Ammam, PHD In a recent collaborative research project published in the PLOS one journal entitled “Risk Factors of Pulmonary Hypertension in Brazilian Patients with Sickle Cell Anemia,” researchers suggest that patients suffering from sickle cell anemia (SCA) have higher...
By Alisa Woods, PhD Cytori Therapeutics recently published a report of 12-month data from the Scleradec-I clinical trial studying hand dysfunction in people with scleroderma. Findings from the 12 patient trial, which was led by Dr. Brigitte Granel and Dr. Guy Magalon of...
By Patricia Silva, PhD A study led by researchers at the Imperial College London in the United Kingdom was recently published in the journal Nature reporting the discovery of a gene involved in pulmonary hypertension pathology. The study is entitled “The zinc transporter ZIP12...
By Patricia Silva, PhD Gilead Sciences, Inc. recently announced the publication of data in The New England Journal of Medicine concerning the AMBITION trial evaluating the combination therapy of Letairis® (ambrisentan) and tadalafil for pulmonary arterial hypertension (PAH). The AMBITION trial (NCT01178073) is a multicenter,...
